Intravenous ferric carboxymaltose accelerates erythropoietic recovery from experimental malarial anemia

The Journal of Infectious Diseases
Lasse MarettyJorgen A L Kurtzhals

Abstract

Iron restriction has been proposed as a cause of erythropoietic suppression in malarial anemia; however, the role of iron in malaria remains controversial, because it may increase parasitemia. To investigate the role of iron-restricted erythropoiesis, A/J mice were infected with Plasmodium chabaudi AS, treated with intravenous ferric carboxymaltose at different times, and compared with untreated controls. Iron treatment significantly increased weight and hemoglobin nadirs and provided enhanced reticulocytosis and faster recovery, compared with controls. Our findings challenge the restrictive use of iron therapy in malaria and show the need for trials of intravenous ferric carboxymaltose as an adjunctive treatment for severe malarial anemia.

References

Apr 1, 1997·British Journal of Haematology·J A KurtzhalsL Hviid
Feb 10, 2004·The Journal of Infectious Diseases·Kai-Hsin ChangMary M Stevenson
Mar 8, 2007·Blood·Abigail A LamikanraDavid J Roberts
May 8, 2008·PloS One·Conor P DohertyAndrew M Prentice
Jul 10, 2009·The Cochrane Database of Systematic Reviews·Juliana U OjukwuMical Paul
Sep 10, 2010·Blood·Lawrence Tim GoodnoughTomas Ganz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.